The investigational allogeneic cellular therapy is believed to impart anti-inflammatory, pro-vascular, and pro-regenerative effects.

The product is being recalled because the incorrect strength of 0.125mg is appearing on the carton labels.

AB-1005 is an investigational gene therapy based on AAV2 containing the human GDNF transgene.

Ahzantive is a vascular endothelial growth factor inhibitor.

Researchers sought to evaluate ketamine as a potentially promising treatment approach.